Analyzing the Credit Card Competition Act of 2023 - Payments Pros: The Payments Law Podcast
North Carolina’s House Bill 130: Energy Choice/Solar Decommissioning Requirement - Now in Effect
Podcast - The Latest on Antitrust and Non-Compete Agreements in Healthcare
Data Privacy Unlocked, A Conversation with Texas Representative Giovanni Capriglione
Data Privacy Unlocked, A Conversation with Michigan Senator Rosemary Bayer
DE Under 3: New Controversial Proposed Rule Affecting Title VII
New Consumer Bankruptcy Reform Act Implications and the 2023 Congressional Outlook - The Consumer Finance Podcast
Webinar Recording: An Overview of the American Data Privacy and Protection Act
All Talk, No Action? The Fintech Regulatory Plot Thickens
Data Privacy Unlocked, A Second Conversation with Joseph Duball of the IAPP
Since the recent Dobbs decision, which overturned Roe v. Wade, companies have been impacted nationwide and have several new legal angles to consider as it relates to their employees and their business
33rd Annual Legislative Seminar - Senator Shelley Moore Capito, R-W.Va.
Podcast: The Briefing by the IP Law Blog - Senator Hawley Targets Disney with So-Called Copyright Reform Bill
The Briefing by the IP Law Blog: Senator Hawley Targets Disney with So-Called Copyright Reform Bill
Congress Tries to Wrangle Cyber and Crypto Industries
New Regulation: Statutes, Pillars, and the Build Back Better Act
The Tax Legislation Process and What to Expect in 2022
Update and Discussion on Legal and Practical Issues
Data Privacy Unlocked, A Conversation with Maureen Mahoney of Consumer Reports
A Different Kind of Advocacy | Amy & Steve Bresnen | Texas Appellate Law Podcast
On July 10, the Senate unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S.150), which seeks to increase competition and lower drug prices by imposing limits on patent litigation related to biological...more
The Situation: Senate Bill 150 ("S.B. 150")—the Affordable Prescriptions for Patients Act of 2023—unanimously passed the Senate and would amend 35 U.S.C. § 272(e) to limit, under certain circumstances, the number of patents...more
On July 13, 2021, the Senate Judiciary Committee’s antitrust panel met to discuss biologic and biosimilar competition and its impact on drug prices. A group of senators, led by Senator Amy Klobuchar, are sponsors of a Senate...more
Senator Orrin Hatch (R-UT) recently introduced a bill titled the “Hatch-Waxman Integrity Act of 2018” (HWIA). Sen. Hatch suggests that the HWIA will (i) “restore the careful balance the Hatch-Waxman Act struck to incentivize...more
Last week, Senator Orrin Hatch of Utah introduced the “Hatch-Waxman Integrity Act of 2018,” which seeks “to restore the careful balance the Hatch-Waxman Act struck to incentivize generic drug development.” ...more
As we reported last month, many state legislatures have passed or are considering biosimilar substitution bills. Alaska, Connecticut, New Hampshire, and Vermont are the latest states to join this list....more